



Noxopharm Limited ([ASX:NOX](#)) | ASX Announcement | 17 November 2021

Noxopharm AGM 2021 Chairman's Address

Sydney 17 November 2021: Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) provides Noxopharm Non-Executive Chairman, Mr Frederick Bart's, address to the 2021 Annual General Meeting of Shareholders.

Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

About Noxopharm

Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and cytokine release syndrome (septic shock).

Veyonda® is the Company's first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda® has two main drug actions – a moderating effect on the ceramide/sphingosine-1-phosphate balance and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immunomodulatory functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiation therapies and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, as well as contributing to an anti-cancer action, but also potentially blocking septic shock.

Noxopharm is running comprehensive drug discovery programs in both oncology and inflammation, and is the major shareholder of US biotechnology company, Nyrada Inc (ASX:NYR), active in the areas of drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Forward Looking Statements



This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.



Noxopharm 2021 AGM Chairman's Address

Fellow Shareholders,

I am delighted to welcome you to the 2021 Annual General Meeting for Noxopharm.

For the second year, the AGM is being conducted in a virtual format and I wish to thank you for joining us. We all hope that 2023 will see a return to an in-person setting.

Before I begin, I would like to take this opportunity to thank our dedicated staff whose hard work has put the company on what is clearly a path to success.

Success can mean different things in biotech. For me it means getting a substantial return on our investment, and the quickest way we are going to achieve that is through attracting a major industry partner who can help shoulder the bulk of the cost of drug development and take our drugs to market, whether that be in conjunction with Noxopharm or on their own. We are rapidly approaching the stage of development where those relationships start.

When I look back at what we have achieved this year, I see us having taken important steps towards that goal.

It starts with having a good understanding of how our isoflavonoid technology platform works. Working with universities around the world, our scientists have made significant progress in that field. Out of a lot of things I could mention, let me pick by way of example, the evidence emerging that one way that Veyonda works is by restoring immune function inside cancers, something called turning tumours from cold to hot.

Most human cancers are cold, meaning that they are devoid of immune function, and restoring that immune function is vital in getting other forms of anti-cancer therapy to work better. That includes chemotherapy, radiotherapy and the new immunotherapies that are attracting so much attention. That one

action puts Veyonda in a class of its own and in our view sets it up to become a very valuable drug.

Intellectual property is only valuable if you can protect it with patents, and on that front we have made important progress this year with key patent claims being allowed in various countries around the use of our drug, Veyonda, in combination with chemotherapy and radiotherapy. These and other patents are going to underpin our vision of seeing Veyonda become a standard treatment to make many other forms of cancer therapy work better.

Patents are only worthwhile if you can back up the claims and show that a drug actually works in a patient.

We started the year with encouraging data in February from the LuPIN -1 trial at St Vincent's Hospital here in Sydney, in which late-stage prostate cancer patients were treated with Veyonda combined with a radio-pharmaceutical called Lutetium PSMA. We were extremely pleased to announce that this combination produced survival outcomes entirely unexpected for men with such advanced cancer and pointing to Veyonda having boosted the effect of the radiotherapy.

Then in August we announced the results of the NOXCOVID trial in which Veyonda was given to people hospitalized with moderate lung failure from COVID-19 disease. 37 out of 38 patients in this Phase 1 trial were able to be discharged from hospital without suffering disease progression. As a result, we now are actively looking to become part of one of a number of global studies in COVID-19 patients and we will keep the market updated about this progress.

To round off the Veyonda clinical program, our IONIC and DARRT-2 studies have started, and these will shortly be joined by our sarcoma study.

By this time next year we hope to have a lot of clinical data behind us and be well on the way to confirming the enormous opportunity we see for Veyonda.

We also have made great strides in expanding the Company beyond Veyonda with a growing pipeline of exciting new anti-cancer drugs, plus the great work underway between our subsidiary company, Pharmorage Pty Ltd, one of Australia's most respected medical research institutions, Hudson Institute of Medical Research (HIMR). I urge you to visit the new Pharmorage website for more information about what is going on in that subsidiary at www.pharmorage.com

On behalf of the Noxopharm Board, I take this opportunity to express our thanks and appreciation to the shareholders for your ongoing support as the Company continues its advance towards its commercial goals.

Yours sincerely,

A handwritten signature in black ink, appearing to be 'FB' with a stylized flourish.

Fred Bart

17 November 2021